Regeneron Pharmaceuticals PPandE Turnover Trend

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

This module enables investors to look at Regeneron Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 311.7 M, Consolidated Income of 476.6 M or Cost of Revenue of 175.6 M, but also many exotic indicators such as Interest Coverage of 77.0381, Long Term Debt to Equity of 0.196 or Calculated Tax Rate of 10.7856. This module is a perfect complement to use when analyzing Regeneron Pharmaceuticals Valuation or Volatility. It can also complement various Regeneron Pharmaceuticals Technical models. Additionally take a look at analysis of Regeneron Pharmaceuticals Correlation with competitors.

Regeneron Pharmaceuticals PPandE Turnover Marginal Breakdown

Showing smoothed PPandE Turnover of Regeneron Pharmaceuticals with missing and latest data points interpolated.
PPandE Turnover10 Years Trend
Increasing
Stable
 PPandE Turnover 
      Timeline 

Regeneron Pharmaceuticals Regression Statistics

Arithmetic Mean 2.75
Geometric Mean 2.59
Coefficient Of Variation 34.87
Mean Deviation 0.71
Median 2.64
Standard Deviation 0.96
Sample Variance 0.92
Range 3.40
R Value 0.29
Mean Square Error 0.93
R Squared 0.08
Significance 0.36
Slope 0.08
Total Sum of Squares 10.13

Regeneron Pharmaceuticals PPandE Turnover Over Time

2017  2.64 
2018  2.72 
2019  2.62 

Other Fundumenentals of Regeneron Pharmaceuticals

Search macroaxis.com